Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase Share XChiesi’s flagship Fabry drug heads for FDA verdict in early 2021https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/
Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
Amicus’ oral Fabry disease drug approved in USDecision follows approval in Europe Share XAmicus’ oral Fabry disease drug approved in UShttps://pharmaphorum.com/news/amicus-oral-fabry-disease-drug-approved/
Amicus set for share of Fabry market after NICE approvalEngland and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment for the Share XAmicus set for share of Fabry market after NICE approvalhttps://pharmaphorum.com/news/amicus-set-share-fabry-market-nice-approval/
